Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Plasma Urate, Cancer Incidence, and All-Cause Mortality: A Mendelian Randomization Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Peripheral Neuropathy - time for better biomarkers?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lipoprotein(a) Should Be Measured in All Individuals Suspected of Having Familial Hypercholesterolemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Observationally, high plasma urate is associated with high risk of cancer. We used a Mendelian randomization design to test the hypothesis that high concentrations of plasma urate are associated with high cancer incidence and all-cause mortality observationally and genetically.

METHODS: We performed observational and genetic analyses using plasma urate and the urate solute carrier family 2 member 9 (SLC2A9) rs7442295 genotype in 86210 individuals from the Copenhagen General Population Study. Cancer and mortality end points were from national cancer and death registries. Incidences and risk of cancer and all-cause mortality were calculated using Cox regression, Fine and Gray competing-risks regression, and instrumental variable analyses.

RESULTS: During a median follow-up time of 3.9 years for cancer and 4.9 years for all-cause mortality, 3243 individuals received a diagnosis of cancer and 3978 died. Observationally, 50% higher plasma urate was associated with multivariable-adjusted hazard ratios of 1.11 (95% CI, 1.05-1.18) for cancer incidence and 1.07 (1.01-1.13) for all-cause mortality. Each A-allele of the SLC2A9 rs7442295 was associated with 9% higher plasma urate and hazard ratios of 1.07 (1.01-1.14) for cancer incidence and 1.07 (1.02-1.13) for all-cause mortality. In instrumental variable analyses, the odds ratios for a genetically determined 50% higher plasma urate was 1.22 (1.02-1.47) for cancer incidence and 1.49 (1.13-1.93) for all-cause mortality.

CONCLUSIONS: High plasma urate was both observationally and genetically associated with high cancer incidence and high all-cause mortality, suggesting causal relationships.

Original languageEnglish
JournalClinical Chemistry
Volume63
Issue number6
Pages (from-to)1151-1160
Number of pages10
ISSN0009-9147
DOIs
Publication statusPublished - Jun 2017

    Research areas

  • Adult, Aged, Aged, 80 and over, Alleles, Cause of Death, Genotype, Glucose Transport Proteins, Facilitative, Humans, Middle Aged, Neoplasms, Risk Factors, Survival Analysis, Uric Acid, Young Adult, Journal Article, Observational Study, Randomized Controlled Trial

ID: 52335831